BioKangtai Advances Oral Pentavalent Rotavirus Vaccine to Phase III Clinical Trial

On April 9, 2025, BioKangtai and its wholly-owned subsidiary BioMinhai announced the initiation of Phase III clinical trials for their Oral Pentavalent Rotavirus Vaccine (Vero Cell). The vaccine targets infants aged 6 weeks to 32 weeks, aiming to prevent rotavirus gastroenteritis. It covers the major serotypes (G1, G2, G3, G4, and G9) responsible for the disease in China. The Phase III trial is designed as a multi-center, randomized, double-blind, placebo-controlled study to evaluate the vaccine’s efficacy, safety, and immunogenicity. This milestone marks a significant step towards enhancing infant health protection. 

BioKangtai remains dedicated to advancing vaccine development through rigorous scientific processes and looks forward to contributing to global public health by providing a safe and effective vaccine option.